Le Lézard
Classified in: Health
Subject: LAW

Johnson // Becker, PLLC Files Elmiron Class Action Lawsuit Against Janssen Pharmaceuticals For Medical Monitoring For Elmiron Side Effects And Injuries


ST. PAUL, Minn., May 19, 2020 /PRNewswire/ -- Johnson // Becker, PLLC is a nationwide plaintiff's law firm with experience representing injured men and women in lawsuits against pharmaceutical and medical device companies. Johnson // Becker has filed a number of Elmiron lawsuits and represents several individuals who allege they have suffered permanent vision loss after use of the drug Elmiron. 

Furthermore, in this action they seek class certification to establish a fund to be used for medical monitoring of patients using Elmiron to monitor the status of their vision.  The case, Allen v. Janssen Pharamceuticals, Inc. et al. was filed in the United States District Court for the Eastern District of Pennsylvania on May 6, 2020.

Janssen Pharmaceuticals, part of the Johnson & Johnson umbrella of companies, is a Pennsylvania corporation.  These companies have marketed Elmiron since the 2000s.  The Plaintiff alleges that the company has never provided any warning of maculopathy or retinopathy associated with use of the drug or warned patients to have regular eye exams to monitor vision while using the drug and seeks class certification to assist patients with these eye exams to monitor their vision.

Timothy J. Becker and Stacy K Hauer of Johnson // Becker are counsel of record. Mr. Becker and Ms. Hauer have a combined experience of more than 40 years of litigating mass tort cases involving pharmaceuticals and medical devices.

Talk to Your Doctor About Elmiron Associated Retinal Maculopathy

If you or a loved one has ever taken Elmiron, you should have your eyes examined by an Ophthalmologist. Download our free PDF guide (https://www.johnsonbecker.com/wp-content/uploads/2020/05/Elmiron-Associated-Pigmentary-Maculopathy-Free-PDF-Guide-Take-to-your-doctor.pdf) that you can share with your primary care provider, urologist, gynecologist or ophthalmologist that provides valuable information on the latest research and discoveries pertaining to Elmiron associated retinal maculopathy.

To learn more about Johnson // Becker and the Elmiron lawsuits we are filing, or to arrange a free, no-obligation case review, please visit Johnson // Becker at https://www.johnsonbecker.com/drug-injuries/elmiron-lawsuit/ or contact the lawyers at (800) 279-6386.

https://www.johnsonbecker.com

SOURCE Johnson // Becker, PLLC


These press releases may also interest you

at 20:35
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

at 18:01
Aflac Incorporated announced today that it has revised the time of its first quarter webcast teleconference call on Thursday, May 2, 2024 to 7:00 a.m. (ET), which is one hour earlier than the originally scheduled 8:00 a.m. start time, to avoid...



News published on and distributed by: